News | January 25, 2022
Control Print’s 3-ply surgical masks receive USFDA 510(K) authorisation
The company has been manufacturing masks since the Covid-19 outbreak in 2020
The company has been manufacturing masks since the Covid-19 outbreak in 2020
Ind-Ra expects revenue growth of over 12% in 2022.
EMBER500RNA Prestain Loading Dye allows single-step denaturing, loading, and bright RNA staining on regular agarose gels
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
Flattish volume growth and subdued new launches were key factors for last month
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Subscribe To Our Newsletter & Stay Updated
